for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Malin Corporation plc

MLCM.I

Latest Trade

2.90EUR

Change

0.10(+3.57%)

Volume

34,150

Today's Range

2.90

 - 

2.92

52 Week Range

2.00

 - 

5.65

As of on the Irish Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2.80
Open
2.92
Volume
34,150
3M AVG Volume
1.34
Today's High
2.92
Today's Low
2.90
52 Week High
5.65
52 Week Low
2.00
Shares Out (MIL)
49.00
Market Cap (MIL)
132.59
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Malin Announces Appointment Of Darragh Lyons As CEO, Results

Malin Corp Says Kymab And LifeArc Announce Strategic Partnership

Malin Corporation Says Kymab Submits Confidential Draft Registration Statement For Proposed IPO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Malin Corporation plc

Malin Corporation plc is an Ireland-based global life sciences company. The Company's businesses include 3D4Medical, which is a technology company; Altan, which is an injectable drug company; AN2H Discovery Limited, which focuses on designing novel small molecule therapeutics; Emba Medical Limited, which offers vascular embolization system; Emba Neuro Limited; Hatteras Venture Partners (HVP), which is a life sciences company; Immunocore, which is a biotechnology company; Jaan Health, which is a healthcare mobile technology company; Kymab Limited, which is a biopharmaceutical company; Melinta Therapeutics, Inc.; Novan, Inc., which is a clinical stage company; Poseida Therapeutics, Inc., which is a human therapeutics company, and Viamet Pharmaceuticals, Inc., which is a drug discovery company. The Company operates through subsidiaries, and focuses on various therapeutic areas, including dermatology, anti-infective, pain, immunology, oncology, neurology, anatomy and other areas.

Industry

Biotechnology & Drugs

Contact Info

Dun Laoghaire, 2 Harbour Road

+353.1.9015700

http://www.malinplc.com/

Executive Leadership

Liam Daniel

Non-Executive Chairman of the Board

Bahija Jallal

Chief Executive Officer, Director

Darragh Fergal Lyons

Chief Financial Officer, Executive Director

Neil McLoughlin

General Counsel, Company Secretary

David Dobrosky

Senior Analyst

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
3.81
Price To Book (MRQ)
0.84
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
42.87
LT Debt To Equity (MRQ)
33.19
Return on Investment (TTM)
-9.45
Return on Equity (TTM)
-8.13

Latest News

BRIEF-Malin Corp Says Poseida raises $142 Mln in Private Financing Round

* MALIN CORP PLC - POSEIDA RAISES $142 MILLION IN SERIES C FINANCING

BRIEF-Malin Corporation says Adrian Howd to assume role of CEO

* MALIN CORPORATION PLC - ADRIAN HOWD, MALIN'S CHIEF INVESTMENT OFFICER, WILL ASSUME ROLE OF CHIEF EXECUTIVE OFFICER WITH EFFECT FROM 1 OCTOBER 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up